Stockpolly
Search
TVGN · NASDAQ · Biotechnology

Tevogen Bio (TVGN)

Develops ExacTcell-based T-cell therapy candidates for COVID-19, cancer and Long COVID.

$6.92
Pre-market−0.25 (−3.49%)
At close$7.17(0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
22298691056556
Research & development1121433333233
119436733322
General & administrative009000733322
Other expenses000000000000
Operating income−2−2−30−9−6−9−10−5−6−5−5−6
−2−241−100000000
Interest income010000000000
Interest expense000000000000
Other non-operating income11−41100000000
Income before tax−4−411−10−6−9−10−6−6−5−5−6
Net income from continuing operations−4−411−10−6−9−10−6−6−5−5−6
Other adjustments000400000000
Net income−4−411−6−6−9−10−6−6−5−5−6
EPS, basic−$1.24−$0.26$4.00−$1.97−$1.74−$2.60−$3.26−$1.53−$1.50−$1.20−$1.61−$1.52
EPS, diluted−$1.24−$0.26−$13.00−$1.97−$1.74−$2.60−$3.26−$1.53−$1.50−$1.20−$1.61−$1.52
Weighted average shares, basic333334344334
Weighted average shares, diluted333334344334
EBITDA−4−312−10−6−9−10−5−5−5−5−6
Depreciation & amortization000000000000
EBIT−4−311−10−6−9−10−6−6−5−6−6